Jazz Pharmaceuticals Enters Material Definitive Agreement

Ticker: JAZZ · Form: 8-K · Filed: Jul 22, 2024 · CIK: 1232524

Jazz Pharmaceuticals PLC 8-K Filing Summary
FieldDetail
CompanyJazz Pharmaceuticals PLC (JAZZ)
Form Type8-K
Filed DateJul 22, 2024
Risk Levelmedium
Pages4
Reading Time4 min
Key Dollar Amounts$0.0001, $289,564,455.52, $2,707,000,000
Sentimentneutral

Sentiment: neutral

Topics: material-definitive-agreement, financial-obligation

Related Tickers: JAZZ

TL;DR

Jazz Pharma signed a big deal, could mean new financial obligations.

AI Summary

On July 19, 2024, Jazz Pharmaceuticals plc entered into a material definitive agreement related to a financial obligation. The company, incorporated in Ireland, filed an 8-K report detailing this event. Specific details regarding the nature of the agreement and the financial obligation are not provided in this excerpt.

Why It Matters

This filing indicates Jazz Pharmaceuticals has entered into a significant agreement that may involve financial commitments, potentially impacting its financial structure and future operations.

Risk Assessment

Risk Level: medium — Entering into material definitive agreements can introduce new financial obligations or strategic shifts that carry inherent risks.

Key Players & Entities

FAQ

What type of material definitive agreement did Jazz Pharmaceuticals plc enter into?

The filing indicates Jazz Pharmaceuticals plc entered into a material definitive agreement, but the specific nature of the agreement is not detailed in this excerpt.

What is the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is July 19, 2024.

Where is Jazz Pharmaceuticals plc incorporated?

Jazz Pharmaceuticals plc is incorporated in Ireland.

What is the SEC file number for Jazz Pharmaceuticals plc?

The SEC file number for Jazz Pharmaceuticals plc is 001-33500.

What is the IRS Employer Identification Number for Jazz Pharmaceuticals plc?

The IRS Employer Identification Number for Jazz Pharmaceuticals plc is 98-1032470.

Filing Stats: 1,061 words · 4 min read · ~4 pages · Grade level 10.1 · Accepted 2024-07-22 07:57:32

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY By: /s/ Philip L. Johnson Name: Philip L. Johnson Title: Executive Vice President and Chief Financial Officer Date: July 22, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing